Nkarta stock skyrockets on heavy volume after upbeat results from cancer-treatment trialMarket Watch • 04/25/22
Nkarta's stock jumps 42% after announcing positive Phase 1 data for experimental CAR-T therapiesMarket Watch • 04/25/22
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell ProgramsGlobeNewsWire • 04/25/22
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy CandidatesGlobeNewsWire • 04/22/22
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022GlobeNewsWire • 04/08/22
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of DirectorsGlobeNewsWire • 03/29/22
Wall Street Analysts See a 478% Upside in Nkarta, Inc. (NKTX): Can the Stock Really Move This High?Zacks Investment Research • 03/22/22
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate HighlightsGlobeNewsWire • 03/17/22
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual MeetingGlobeNewsWire • 03/08/22
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AMLGlobeNewsWire • 12/16/21
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and ExpositionGlobeNewsWire • 12/13/21
Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 11/15/21
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual MeetingGlobeNewsWire • 11/12/21
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual MeetingGlobeNewsWire • 10/01/21
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company HeadquartersGlobeNewsWire • 07/14/21